WO1989002738A1 - Sustained-release nifedipine formulation - Google Patents
Sustained-release nifedipine formulation Download PDFInfo
- Publication number
- WO1989002738A1 WO1989002738A1 PCT/GB1988/000779 GB8800779W WO8902738A1 WO 1989002738 A1 WO1989002738 A1 WO 1989002738A1 GB 8800779 W GB8800779 W GB 8800779W WO 8902738 A1 WO8902738 A1 WO 8902738A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- parts
- formulation
- coating
- nifedipine
- core
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
Abstract
Description
Claims
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB878722306A GB8722306D0 (en) | 1987-09-22 | 1987-09-22 | Sustained-release formulation |
GB8722306 | 1987-09-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1989002738A1 true WO1989002738A1 (en) | 1989-04-06 |
Family
ID=10624201
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1988/000779 WO1989002738A1 (en) | 1987-09-22 | 1988-09-22 | Sustained-release nifedipine formulation |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP0386023A1 (en) |
JP (1) | JPH03500288A (en) |
GB (1) | GB8722306D0 (en) |
WO (1) | WO1989002738A1 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992001446A1 (en) * | 1990-07-20 | 1992-02-06 | Aps Research Limited | Sustained-release formulations |
EP0557244A1 (en) * | 1992-02-17 | 1993-08-25 | Siegfried Pharma AG | Dosage forms having prolonged active-ingredient release |
WO1994005262A1 (en) * | 1992-09-10 | 1994-03-17 | F.H. Faulding & Co. Limited | Sustained release matrix composition |
EP0599282A1 (en) * | 1992-11-27 | 1994-06-01 | BIOPROGRESS S.p.A. | Pharmaceutical compositions containing ursodeoxycholic acid |
US5439687A (en) * | 1992-02-17 | 1995-08-08 | Siegfried Pharma Ag | Dosage forms having zero-order dihydropyridine calcium antagonist release |
US5455046A (en) * | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US5594013A (en) * | 1992-01-13 | 1997-01-14 | Ethical Pharmaceuticals Limited | Pharmaceutical compositions containing nifedipine and process for the preparation thereof |
US5662933A (en) * | 1993-09-09 | 1997-09-02 | Edward Mendell Co., Inc. | Controlled release formulation (albuterol) |
US6048548A (en) * | 1993-09-09 | 2000-04-11 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems-amorphous drugs |
US6056977A (en) * | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
US6093420A (en) * | 1996-07-08 | 2000-07-25 | Edward Mendell Co., Inc. | Sustained release matrix for high-dose insoluble drugs |
WO2002072064A2 (en) * | 2001-03-09 | 2002-09-19 | Dow Global Technologies Inc. | Granular composition comprising an active compound and a cellulose ether and the use thereof |
US6726930B1 (en) | 1993-09-09 | 2004-04-27 | Penwest Pharmaceuticals Co. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US9439851B2 (en) * | 2004-03-25 | 2016-09-13 | Sun Pharma Advanced Research Company Ltd. | Gastric retention system |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4331930B2 (en) * | 2001-10-17 | 2009-09-16 | 武田薬品工業株式会社 | High content granules of acid labile drugs |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0123470A1 (en) * | 1983-04-21 | 1984-10-31 | ELAN CORPORATION, Plc | Controlled absorption pharmaceutical composition |
EP0142561A1 (en) * | 1981-09-14 | 1985-05-29 | Kanebo, Ltd. | Long-acting nifedipine preparation |
WO1986001717A1 (en) * | 1984-09-14 | 1986-03-27 | Pharmatec S.P.A. | Controlled release nifedipine preparation |
EP0255404A1 (en) * | 1986-08-01 | 1988-02-03 | APS Research Limited | Sustained release ibuprofen formulation |
-
1987
- 1987-09-22 GB GB878722306A patent/GB8722306D0/en active Pending
-
1988
- 1988-09-22 WO PCT/GB1988/000779 patent/WO1989002738A1/en not_active Application Discontinuation
- 1988-09-22 EP EP19880908289 patent/EP0386023A1/en not_active Ceased
- 1988-09-22 JP JP50763388A patent/JPH03500288A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0142561A1 (en) * | 1981-09-14 | 1985-05-29 | Kanebo, Ltd. | Long-acting nifedipine preparation |
EP0123470A1 (en) * | 1983-04-21 | 1984-10-31 | ELAN CORPORATION, Plc | Controlled absorption pharmaceutical composition |
WO1986001717A1 (en) * | 1984-09-14 | 1986-03-27 | Pharmatec S.P.A. | Controlled release nifedipine preparation |
EP0255404A1 (en) * | 1986-08-01 | 1988-02-03 | APS Research Limited | Sustained release ibuprofen formulation |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992001446A1 (en) * | 1990-07-20 | 1992-02-06 | Aps Research Limited | Sustained-release formulations |
US5594013A (en) * | 1992-01-13 | 1997-01-14 | Ethical Pharmaceuticals Limited | Pharmaceutical compositions containing nifedipine and process for the preparation thereof |
EP0557244A1 (en) * | 1992-02-17 | 1993-08-25 | Siegfried Pharma AG | Dosage forms having prolonged active-ingredient release |
US5439687A (en) * | 1992-02-17 | 1995-08-08 | Siegfried Pharma Ag | Dosage forms having zero-order dihydropyridine calcium antagonist release |
WO1994005262A1 (en) * | 1992-09-10 | 1994-03-17 | F.H. Faulding & Co. Limited | Sustained release matrix composition |
EP0599282A1 (en) * | 1992-11-27 | 1994-06-01 | BIOPROGRESS S.p.A. | Pharmaceutical compositions containing ursodeoxycholic acid |
US5958456A (en) * | 1993-09-09 | 1999-09-28 | Edward Mendell Co., Inc. | Controlled release formulation (albuterol) |
US6245356B1 (en) | 1993-09-09 | 2001-06-12 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems-amorphous drugs |
US5512297A (en) * | 1993-09-09 | 1996-04-30 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US5662933A (en) * | 1993-09-09 | 1997-09-02 | Edward Mendell Co., Inc. | Controlled release formulation (albuterol) |
US5667801A (en) * | 1993-09-09 | 1997-09-16 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US5846563A (en) * | 1993-09-09 | 1998-12-08 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US5455046A (en) * | 1993-09-09 | 1995-10-03 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US6048548A (en) * | 1993-09-09 | 2000-04-11 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems-amorphous drugs |
US6726930B1 (en) | 1993-09-09 | 2004-04-27 | Penwest Pharmaceuticals Co. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US5554387A (en) * | 1993-09-09 | 1996-09-10 | Edward Mendell Co., Ltd. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US6136343A (en) * | 1993-09-09 | 2000-10-24 | Edward Mendell Co., Inc. | Sustained release heterodisperse hydrogel systems for insoluble drugs |
US6093420A (en) * | 1996-07-08 | 2000-07-25 | Edward Mendell Co., Inc. | Sustained release matrix for high-dose insoluble drugs |
US6245355B1 (en) | 1996-07-08 | 2001-06-12 | Edward Mendell Co., Inc. | Sustained release matrix for high-dose insoluble drugs |
US6689386B2 (en) | 1996-07-08 | 2004-02-10 | Penwest Pharmaceuticals Co. | Sustained release matrix for high-dose insoluble drugs |
US6537578B1 (en) | 1997-10-15 | 2003-03-25 | Penwest Pharmaceuticals Co. | Once-a-day controlled release sulfonylurea formulation |
US6056977A (en) * | 1997-10-15 | 2000-05-02 | Edward Mendell Co., Inc. | Once-a-day controlled release sulfonylurea formulation |
US6875793B2 (en) | 1997-10-15 | 2005-04-05 | Penwest Pharmaceuticals Co. | Once-a-day controlled release sulfonylurea formulation |
WO2002072064A2 (en) * | 2001-03-09 | 2002-09-19 | Dow Global Technologies Inc. | Granular composition comprising an active compound and a cellulose ether and the use thereof |
WO2002072064A3 (en) * | 2001-03-09 | 2003-03-06 | Dow Global Technologies Inc | Granular composition comprising an active compound and a cellulose ether and the use thereof |
US9439851B2 (en) * | 2004-03-25 | 2016-09-13 | Sun Pharma Advanced Research Company Ltd. | Gastric retention system |
Also Published As
Publication number | Publication date |
---|---|
JPH03500288A (en) | 1991-01-24 |
EP0386023A1 (en) | 1990-09-12 |
GB8722306D0 (en) | 1987-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5051263A (en) | Controlled-release formulations | |
EP0255404B1 (en) | Sustained release ibuprofen formulation | |
EP1562573B1 (en) | Pharmaceutical pellets comprising tamsulosin and a process for making the same | |
EP0142561B1 (en) | Long-acting nifedipine preparation | |
EP0386967B1 (en) | A drug-release controlling coating material for long acting formulations | |
US5340589A (en) | Low solubility drug-coated bead compositions | |
EP0213083A2 (en) | Controlled release tablet | |
SK78694A3 (en) | Solid medicamentous form with regulated release of drug and method of its preparing | |
JP2003518483A (en) | Improved pharmaceutical composition for poorly soluble drugs | |
WO1989002738A1 (en) | Sustained-release nifedipine formulation | |
NZ232030A (en) | Sustained release pharmaceutical pellet composition; theophylline compound core, coated to allow faster release rate in intestine | |
AU770293B2 (en) | Sustained-release pharmaceutical preparation containing tilidine mesylate as active ingredient | |
EP1154762B1 (en) | Pharmaceutical capsule compositions containing loratadine and pseudoephedrine | |
JP2003528905A (en) | Stavudine-containing sustained release beads | |
JP3110794B2 (en) | Preparation containing 1,4-dihydropyridine derivative | |
CA2216277C (en) | Controlled release pharmaceutical compositions for the oral administration containing nifedipine as active substance | |
US5445830A (en) | Highly absorbable pharmaceutical composition | |
EP0410422B1 (en) | A highly absorbable pharmaceutical composition | |
EP0297866A2 (en) | Therapeutic agents | |
US20050106253A1 (en) | Pharmaceutical pellets comprising tamsulosin | |
EP0377439B1 (en) | Controlled-release, low-dose aspirin | |
EP0908177B1 (en) | Procedure to form pharmaceutical compositions in spherical pills or granules of controlled and sustained action that contain as active agent Bromazepam and pharmaceutical compositions obtained by said procedure | |
MXPA01002821A (en) | Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): JP US |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE FR GB IT LU NL SE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1988908289 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1988908289 Country of ref document: EP |
|
WWR | Wipo information: refused in national office |
Ref document number: 1988908289 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1988908289 Country of ref document: EP |